NASDAQ$ARQT
Arcutis Biotherapeutics Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Arcutis Biotherapeutics Inc reported Q2 2025 product revenue of $81.5 million, up 164% year-over-year, driven by continued ZORYVE commercialization.
The company achieved net product revenue of $81.5 million in the second quarter, reflecting strong demand across ZORYVE cream 0.3%, foam, and cream 0.15%. Operating expenses totaled $96.1 million, resulting in a net loss of $15.9 million or $0.13 per share. Cash and cash equivalents stood at $72.7 million at quarter end.
- Q2 2025 product revenue reached $81.5 million, a 164% increase from $30.9 million in Q2 2024.
- ZORYVE foam contributed $39.2 million, ZORYVE cream 0.3% $27.7 million, and ZORYVE cream 0.15% $14.6 million.
- Net loss improved to $15.9 million from $52.3 million in the prior-year quarter.
- R&D expenses were $19.5 million and SG&A expenses were $69.2 million for the quarter.
Headline financials
Revenue & EPS history
Arcutis · Revenue · Quarterly
$81.5M
Revenue by segment
Arcutis · $81.5M total across 3 segments · Q2 2025
- ZORYVE foam$39.2M—48.1%
- ZORYVE cream 0.3%$27.7M—34.0%
- ZORYVE cream 0.15%$14.6M—17.9%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
+1.8%
Avg return
Earnings day
+1.1%
Avg return
5 days after
-0.5%
Avg return
30 days after
64%
16 / 25 earnings
Positive
+27.2%
Q3 2025
Best reaction
-15.6%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +3.2% | -9.3% | -9.4% | |
| Q4 2025 | +5.7% | -12.6% | -21.4% | |
| Q3 2025 | +27.2% | +28.9% | +57.6% | |
| Q1 2025 | -4.6% | +0.5% | +0.3% | |
| Q4 2024 | +8.4% | +5.2% | +28.9% | |
| Q3 2024 | +11.8% | +16.6% | +33.3% | |
| Q2 2024 | -14.6% | -13.1% | +7.1% | |
| Q1 2024 | +15.6% | +15.1% | +16.9% | |
| Q4 2023 | +7.4% | +21.5% | +2.3% | |
| Q3 2023 | +5.4% | -0.9% | -10.4% | |
| Q2 2023 | -2.0% | -6.5% | -21.0% | |
| Q1 2023 | -15.6% | -29.3% | -29.8% | |
| Q4 2022 | +4.4% | -2.7% | -31.8% | |
| Q3 2022 | +0.6% | +3.1% | -8.4% | |
| Q2 2022 | +13.2% | +11.8% | +8.6% | |
| Q1 2022 | -11.8% | -14.1% | -3.5% | |
| Q4 2021 | +1.1% | +12.6% | +10.7% | |
| Q3 2021 | -7.5% | -6.9% | -35.6% | |
| Q2 2021 | +3.1% | +5.2% | +4.1% | |
| Q1 2021 | -3.4% | -1.8% | -23.1% | |
| Q4 2020 | -0.1% | +3.6% | -10.5% | |
| Q3 2020 | -3.8% | +8.9% | +37.1% | |
| Q2 2020 | +1.7% | +1.8% | -6.5% | |
| Q4 2019 | +0.0% | -4.6% | -4.6% | |
| Q1 2020 | +0.0% | -4.6% | -4.6% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro